Novo Nordisk A/S (NVO)
Novo Nordisk A/S (NVO) carries a ŷRobot AI score of 54 out of 100. The model's fair value estimate is $40.36, 3.1% below the last close of $41.64. The chart signal reads Hold.
| Metric | NVO |
|---|---|
| AI score | 54 / 100 |
| Chart signal | Hold |
| Fair value estimate | $40.36 |
| Upside to fair value | -3.1% |
| Previous close | $41.64 |
| P/E | 10.65 |
| Price / sales | 2.58 |
| Market cap | $181.14B |
| EPS | 3.96 |
| Revenue growth | 20.0% |
| 1-year price change | 13.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about NVO
Is NVO overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates Novo Nordisk A/S (NVO) at $40.36 against a last close of $41.64, implying 3.1% downside to the model's estimate.
Is NVO's chart signal bullish or bearish?
The chart-signal model classifies NVO as Neutral as of Nov 13, 2026, with a signal score of 0.00 on a -1 to 1 scale.
What is NVO's ŷRobot AI score?
NVO scores 54 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is NVO stock expensive on P/E and P/S?
NVO trades at 10.7 times earnings and 2.6 times sales as of Nov 13, 2026.
What does NVO's seasonal forecast show?
ŷRobot's seasonal forecast curve for NVO reads +2.3% at 30 days, +6.5% at 90 days, and +13.6% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is NVO growing?
Novo Nordisk A/S's revenue growth is +20.0% and free-cash-flow growth is -58.2% on the latest reported figures.
NVO chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.